Benralizumab for eosinophilic granulomatosis with polyangiitis

Conclusions Benralizumab appears to be an effective treatment for refractory asthma or ENT manifestations in EGPA and allows GC-sparing. However, its efficacy was lower after prior failure of mepolizumab.

http://ard.bmj.com/cgi/content/short/82/12/1580?rss=1

Source: Annals of the Rheumatic Diseases - November 10, 2023 Category: Rheumatology Authors: Cottu, A., Groh, M., Desaintjean, C., Marchand-Adam, S., Guillevin, L., Puechal, X., Beaumesnil, S., Lazaro, E., Samson, M., Taille, C., Durel, C.-A., Diot, E., Nicolas, S., Guilleminault, L., Ebbo, M., Cathebras, P., Dupin, C., Yildiz, H., Belfeki, N., P Tags: ARD, Vasculitis Source Type: research